Download PDF

1. Company Snapshot

1.a. Company Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.


In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables.Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services.It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers.


It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati.The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Show Full description

1.b. Last Insights on QIA

Qiagen's recent performance was driven by strong Q3 2025 earnings, surpassing sales targets, and expanding its portfolio. The company's net profit margin climbed to 18.3% from 3.7%, with annual earnings growth hitting 413.6%. Qiagen's $500 million share repurchase and acquisition of Parse also contributed to its positive momentum. Additionally, the company's 2026 priorities, including advancing product commercialization and regulatory milestones, are expected to drive growth. Its estimated fair value is $59.85, suggesting potential undervaluation by 24%.

1.c. Company Highlights

2. QIAGEN Delivers Solid FY2025 Results, Sets Ambitious 2026 Outlook

QIAGEN reported net sales of $540 million in Q4 2025, growing 1% at constant exchange rates (CER), and $2.09 billion for the full year, up 5% at CER. Adjusted diluted EPS was $0.62 at CER for the quarter and $2.40 at CER for the full year, exceeding the company's targets. The growth pillars, including Sample technologies, QuantiFERON, QIAstat, QIAcuity, and QIAGEN Digital Insights, delivered combined sales of $1.49 billion at CER in 2025, with 8% growth at CER. As Thierry Bernard, CEO, noted, "We are on track to achieve at least $2 billion in combined sales from these pillars by 2028."

Publication Date: Feb -16

📋 Highlights
  • Full-Year Sales Growth:: Net sales reached $2.09 billion in 2025, reflecting a 5% increase at constant exchange rates (CER), driven by growth in key product lines.
  • Growth Pillars Performance:: Combined sales from Sample technologies, QuantiFERON, QIAstat, QIAcuity, and QIAGEN Digital Insights totaled $1.49 billion in 2025, growing 8% at CER, with a 2028 target of at least $2 billion.
  • Profitability & Free Cash Flow:: Adjusted operating income margin rose 80 basis points to 29.5% in 2025, while free cash flow hit $453 million, and over $1.1 billion was returned to shareholders since 2024.
  • 2026 Guidance:: QIAGEN expects 2026 sales growth of at least 5% at CER, with adjusted EPS of $2.50 CER, supported by new product launches and operational efficiency initiatives.
  • QuantiFERON Momentum:: QuantiFERON achieved 10% CER growth in 2025, with a projected $535 million target for 2026, and the company confirmed a $600 million 2028 growth target amid competitive pricing strategies.

Segment Performance

Sample technologies grew 5% at CER in Q4 and 2% at CER for the full year, while QuantiFERON delivered 5% CER growth in Q4 and 10% CER growth for the full year. QIAstat grew 15% at CER in Q4 and 24% CER for the full year. The company's growth pillars are expected to continue driving sales growth, with Sample Technologies targeting sales of around $720 million CER in 2026.

Profitability and Cash Flow

QIAGEN made progress on profitability and cash flow, with an adjusted operating income margin of 29.5% for 2025, up 80 basis points from 2024. The company generated solid free cash flow of $453 million in 2025 and returned over $1.1 billion to shareholders since 2024.

Outlook and Valuation

For 2026, QIAGEN expects sales growth of at least 5% CER and adjusted earnings per share of at least $2.50 at CER. The company's guidance assumptions include a 5% reported revenue growth, flat operating margin, and a reduced share count to 209 million. With a P/E Ratio of 25.78 and an EV/EBITDA of 15.61, the market is pricing in a certain level of growth. Analysts estimate next year's revenue growth at 5.9%, which is slightly higher than the company's guidance. Actual EPS came out at $0.528, relative to estimates at $0.4664, indicating a positive surprise.

Growth Prospects

QIAGEN has a strong pipeline of new product launches, including QIAsprint Connect and QIAmini, and continues to invest in its growth pillars. The company expects its growth pillars to continue growing in 2026, driven by factors such as new product launches and improving funding trends. With a ROE of 11.85% and an ROIC of 7.8%, the company is generating returns above its cost of capital.

3. NewsRoom

Card image cap

Immunoassay for Neurological Biomarkers Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

Feb -26

Source:

Card image cap

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

Feb -19

Source:

Card image cap

Statutory Profit Doesn't Reflect How Good Qiagen's (NYSE:QGEN) Earnings Are

Feb -17

Source:

Card image cap

Assessing Qiagen (QGEN) Valuation After Recent Share Price Momentum And Perceived Discount

Feb -16

Source:

Card image cap

Qiagen Q4 Earnings Call Highlights

Feb -07

Source:

Card image cap

QGEN's Q4 Earnings Meet Estimates, Revenues Up Y/Y, Stock Down

Feb -06

Source:

Card image cap

Qiagen NV (QGEN) Q4 2025 Earnings Call Highlights: Strong Growth Amidst Challenges

Feb -05

Source:

Card image cap

Qiagen (QGEN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Feb -05

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.24%)

6. Segments

Consumables and Related

Expected Growth: 5%

Qiagen's Consumables and Related segment growth is driven by increasing demand for molecular diagnostics, particularly in infectious disease testing and companion diagnostics. Additionally, the company's expanding portfolio of assays and instruments, such as the QIAstat-Dx and NeuMoDx systems, is contributing to growth. Furthermore, Qiagen's strategic partnerships and acquisitions are enhancing its market presence and driving revenue growth.

Instrumentation

Expected Growth: 7%

Qiagen N.V.'s 7% growth driven by increasing demand for molecular diagnostics, particularly in infectious disease testing and personalized healthcare. Expanding presence in emerging markets, strategic partnerships, and innovative product launches also contribute to growth. Additionally, the company's focus on digitalization and automation of laboratory workflows enhances operational efficiency and drives revenue.

7. Detailed Products

QIAprep&

A series of automated nucleic acid purification systems for high-throughput laboratories

QIAGEN PCR Systems

A range of thermal cyclers and real-time PCR systems for amplification and detection of nucleic acids

GeneReader NGS System

A next-generation sequencing (NGS) system for targeted gene panels and whole-exome sequencing

QIAseq Targeted DNA Panels

Pre-designed and custom panels for targeted DNA sequencing

QuantiFERON-TB Gold

A diagnostic test for latent tuberculosis infection

artus molecular diagnostics

A range of CE-IVD marked PCR assays for infectious disease detection

QIAGEN Bioinformatics

A suite of bioinformatics tools and software for NGS data analysis

CLC Genomics Workbench

A bioinformatics platform for NGS data analysis and interpretation

8. Qiagen N.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Qiagen N.V. operates in the life sciences industry, which is characterized by a moderate threat of substitutes. While there are alternative products and services available, Qiagen's proprietary technologies and strong brand recognition help to mitigate this threat.

Bargaining Power Of Customers

Qiagen N.V. has a diverse customer base, including academic and government institutions, pharmaceutical and biotechnology companies, and clinical laboratories. While customers have some bargaining power, Qiagen's strong brand and product offerings help to maintain a balance of power.

Bargaining Power Of Suppliers

Qiagen N.V. has a diverse supplier base, and the company is not heavily dependent on any single supplier. This reduces the bargaining power of suppliers, giving Qiagen more control over its supply chain.

Threat Of New Entrants

The life sciences industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. These barriers make it difficult for new entrants to challenge Qiagen's market position.

Intensity Of Rivalry

The life sciences industry is highly competitive, with several established players competing for market share. Qiagen N.V. faces intense competition from companies such as Thermo Fisher Scientific, Illumina, and Agilent Technologies, which can lead to pricing pressure and increased marketing expenses.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 28.69%
Debt Cost 4.39%
Equity Weight 71.31%
Equity Cost 6.03%
WACC 5.56%
Leverage 40.24%

11. Quality Control: Qiagen N.V. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Clínica Baviera

A-Score: 6.8/10

Value: 3.6

Growth: 8.2

Quality: 7.4

Yield: 7.5

Momentum: 7.0

Volatility: 7.0

1-Year Total Return ->

View Full Report
Stock-Card
bioMérieux

A-Score: 5.0/10

Value: 2.1

Growth: 5.3

Quality: 6.6

Yield: 1.2

Momentum: 6.0

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Qiagen

A-Score: 5.0/10

Value: 2.7

Growth: 4.6

Quality: 7.0

Yield: 4.4

Momentum: 2.5

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Eurofins Scientific

A-Score: 4.8/10

Value: 3.0

Growth: 6.1

Quality: 4.1

Yield: 1.9

Momentum: 7.5

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Synlab

A-Score: 4.2/10

Value: 5.7

Growth: 8.0

Quality: 3.8

Yield: 1.9

Momentum: 4.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
DiaSorin

A-Score: 4.1/10

Value: 4.6

Growth: 5.0

Quality: 7.6

Yield: 2.5

Momentum: 0.0

Volatility: 5.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

41.57$

Current Price

41.57$

Potential

-0.00%

Expected Cash-Flows